| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 167.20 | 5.3% | 7.8% |
| Total Income | 167.20 | 5.3% | 7.8% |
| Expenditure | 203.23 | 2.5% | 8.6% |
| PBT | -30.02 | 14.2% | 39.0% |
| Net Profit | -37.27 | 7.2% | 21.9% |
| OPM | -21.54% | 3.34pp | 0.85pp |
| NPM | -22.29% | 2.99pp | 2.58pp |
| EPS | -0.33 | 8.3% | 17.9% |
Novocure Reports Q3 2025 Revenue of $167 Million, Up 8% Y-o-Y
04 May 2026 · 4 May, 8:29 am
Summary
Novocure reported a solid third quarter with net revenues of $167 million, an 8% increase compared to the same period in 2024. This growth was primarily driven by active patient growth and exchange rate benefits. The company's gross margin was 73%, a decrease from 77% in the prior year, impacted by the rollout of the Head Flexible Electrode (HFE) transducer array, costs associated with treating NSCLC patients, and increased tariffs. As of September 30, 2025, there were 4,416 total active patients on TTFields therapy globally. Novocure anticipates submitting a PMA application to the FDA for the treatment of brain metastases from NSCLC in Q4 2025.
Key Highlights
- 1
Novocure's third quarter net revenues reached $167 million, reflecting an 8% increase year-over-year.
- 2
As of September 30, 2025, Novocure had 4,416 active patients on therapy.
- 3
The U.S., Germany, France, and Japan contributed $96.6 million, $20.3 million, $19.6 million, and $9.4 million in revenue, respectively.
- 4
Revenue from Optune Lua® in the quarter was $3.1 million, including $1.6 million from non-small cell lung cancer (NSCLC) and $1.5 million from malignant pleural mesothelioma (MPM).
- 5
Gross margin for the quarter was 73%, compared to 77% in the prior year.
- 6
Research, development and clinical study expenses for the quarter were $54.0 million, a 4% increase from the same period in 2024.
- 7
As of September 30, 2025, there were 4,277 Optune Gio active patients on therapy, an increase of 5% from the same period in 2024.
Management Comments
Ashley Cordova
Q3 was a solid quarter with steady commercial execution in glioblastoma, geographic expansion, and material progress for our clinical and product development pipelines. With four indications expected in market by year-end 2026, we are well on our way to becoming a platform therapy company — and we remain sharply focused on reaching profitability and expanding patient impact.”
Informational and educational content only. Not investment advice.